About this event

  • Date and time Tue 28 Apr 2020 from 8:45am to 5:00pm
  • Location Royal Society of Medicine
  • Organised by Endocrinology and Diabetes

This meeting is a unique opportunity to learn about new strategies to lower cardiovascular risk, heart failure hospitalisation and mortality in type 2 diabetes patients by using novel anti-diabetes agent. Benefits, rational indications and potential side effects will be discussed by experts in the field.

You will hear about the challenges in managing CVD risk, heart failure and renal disease in diabetes and receive an update on recent clinical trials results, focusing on SGLT2 inhibitors and GLP-1 receptor agonists, highlighting these drugs benefits beyond glycaemic control.

We will promote understanding and communication between general practitioners, cardiologists, nephrologists and endocrinologists working together.

Topics include

  • Update on reducing thrombosis risk in diabetes, participants will learn to rationally use novel anti-thrombosis agents in high risk patients.
  • Discussing the recent clinical trials results on GLP-1 RAs and SGLT2 inhibitors in Type 2 diabetes highlighting these agents benefits in reducing CVD risk, heart failure and kidney disease. Participants will learn how to use these agents rationally and safely promoting collaboration between endocrinologists, primary care, cardiologists and nephrologists.


Earlybird pricing available until 29 January 2020.


RSM Fellow RSM Associate RSM Retired Fellow RSM Trainee RSM Student
£95.00 £55.00 £55.00 £55.00 £30.00

Non - Member

Consultant / GP AHP / Nurse / Midwife Trainee Student
£150.00 £75.00 £75.00 £45.00


View the programme

Registration, tea and coffee
Welcome and introduction

Chair: Dr Abdul Lakhdar, Consultant Endodocrinologist, Barts Health NHS Trust

An update on the management of thrombosis risk in diabetes

Dr Ramzi Ajjan, Consultant in Diabetes, Endocrinology and Thrombosis, Leeds Teaching Hospitals NHS Trust

The deadly duo of heart failure and diabetes: Challenges in management

Dr Raj Amersey, Consultant Cardiologist, Barts Health NHS Trust

Tea and coffee break
The multifactorial benefits of GLP-1 RAs beyond glycaemic control

Professor Gerry McKay, Consultant Physician and Clinical Pharmacologist, Glasgow

GLP-1 Ras - where do they fit in cardiovascular risk management?

Professor Neil Poulter, Professor of Preventative Cardiovascular Medicine, London

Panel discussion

Chair: Dr Ketan Dhatariya, President, Endocrinology and Diabetes Section, Royal Society of Medicine

The renoprotecive effects of SGLT2i

Professor David Wheeler, University College London and Honorary Consultant Nephrologist, Royal Free Hospital

Heart failure, diabetes and SGLT2i: Time to change practice?

To be confirmed

Tea and coffee break
Should cardiologists and nephrologists prescribe SGLT1i?

To be confirmed

Diabetes and cardiovascular disease: Time for a multifactorial approach

To be confirmed

Panel discussion
Concluding remarks
Close of meeting


Royal Society of Medicine, 1 Wimpole St, Marylebone, London, W1G 0AE, United Kingdom